Paper Details

  1. Home
  2. Paper Details

Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.

Author: MamikonyanEugenia, MelvinEmilie, WeintraubDaniel, XieSharon X

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study determined the efficacy and tolerability of rivastigmine for PD-MCI.
Paper Details　
Original Abstract of the Article :
Mild cognitive impairment (MCI) in Parkinson's disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/mds.26236

データ提供：米国国立医学図書館（NLM）

Rivastigmine for Mild Cognitive Impairment in Parkinson's Disease: A Desert Oasis of Hope

Parkinson's disease, a neurodegenerative disorder that affects movement, can also impact cognitive function. Mild cognitive impairment (MCI) in Parkinson's disease is like a subtle desert sandstorm, slowly affecting cognitive abilities. This research explores the potential benefits of rivastigmine, a medication like a desert oasis, in improving cognitive function in individuals with PD-MCI.

The researchers, acting as diligent desert guides, conducted a randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of rivastigmine in patients with PD-MCI. They observed a trend toward improvement in global cognition, disease-related health status, and anxiety severity in patients receiving rivastigmine.

The study's findings suggest that rivastigmine may offer a potential oasis of hope for individuals with PD-MCI, potentially improving cognitive function and overall quality of life.

A Glimmer of Hope: Rivastigmine for PD-MCI

The study's results provide a glimmer of hope for individuals with PD-MCI. The researchers observed a trend toward improvement in cognitive function, particularly on a performance-based measure of cognitive abilities.

Navigating the Desert: Understanding the Limitations

This research underscores the importance of further investigation into the potential benefits of rivastigmine for PD-MCI. While the study showed promising trends, further research is needed to confirm its effectiveness and explore its long-term impact.

Dr. Camel's Conclusion

In the harsh desert of Parkinson's disease, rivastigmine offers a potential oasis of hope, providing a glimmer of relief for individuals struggling with cognitive impairment. However, further research is needed to fully understand its long-term benefits and optimize its use for patients with PD-MCI.

Date :
  1. Date Completed 2016-04-04
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

25914281

DOI: Digital Object Identifier

10.1002/mds.26236

Related Literature

Article Analysis
・Effects of rivastigmine transdermal patch
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.